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ABSTRACT: A glucose-responsive closed-loop insulin delivery system mimicking pancreas
activity without long-term side effect has the potential to improve diabetic patients’ health and
quality of life. Here, we developed a novel glucose-responsive insulin delivery device using a
painless microneedle-array patch containing insulin-loaded vesicles. Formed by self-assembly of
hypoxia and H2O2 dual-sensitive diblock copolymer, the glucose-responsive polymersome-
based vesicles (d-GRPs) can disassociate and subsequently release insulin triggered by H2O2
and hypoxia generated during glucose oxidation catalyzed by glucose specific enzyme.
Moreover, the d-GRPs were able to eliminate the excess H2O2, which may lead to free radical-
induced damage to skin tissue during the long-term usage and reduce the activity of GOx. In
vivo experiments indicated that this smart insulin patch could efficiently regulate the blood
glucose in the chemically induced type 1 diabetic mice for 10 h.
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Diabetes mellitus is a chronic disease associated withelevated glucose in the blood, which currently affects 415
million people worldwide.1,2 Insulin, a hormone to help cells
take in glucose for energy, is essential for the treatment of type
1 and advanced type 2 diabetic patients in order to maintain
normoglycemia.3 However, the traditional exogenous insulin
injection does not closely match the physiological release of
insulin, often resulting in inadequate glycemic control2,4 and
subsequent consequences such as limb amputation, blindness,
and kidney failure. In addition, overtreatment with insulin may
lead to hypoglycemia, which can cause behavioral and cognitive
disturbance, seizures, loss of consciousness, brain damage, and
even death.5 A “smart” glucose-responsive insulin delivery
system that can mimic the β-cells to “secrete” insulin in
response to a high blood glucose level (BGL) is desirable to
regulate glycemia with minimal effort and to improve the health
and quality of life for diabetic patients.1,2,6,7
In order to achieve this goal, such closed-loop systems
usually consist of a glucose monitoring module and an insulin
releasing module.1,2 The current closed-loop electromechanical
systems include a continuous glucose sensor and an external
insulin infusion pump.2 However, there are still some
challenges that limit the application of these systems, such as
lag in blood glucose feedback and biofouling.8 Alternatively,
chemically controlled glucose-responsive systems have been
widely investigated during the last few decades.1,2,7 Typically,
the insulin embedded matrix with glucose-responsive elements
can adjust the insulin release rate through structural changes
such as swelling, shrinking, degradation, or dissociation in
response to ambient glucose levels.9−11 The common glucose-
responsive elements include glucose oxidase (GOx),10−15
phenylboronic (PBA),16,17 and glucose-binding protein
(GBP).18 Despite these available chemistries, few synthetic
glucose-responsive systems show promise in vivo. Challenges
remain to demonstrate a system consisting of fast responsive-
ness with kinetics similar to a healthy pancreas, biocompatibility
without long-term side effects, and ease of administration.
GOx is an enzyme that can catalyze the oxidation of glucose
in the presence of oxygen
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Previous glucose-responsive systems using GOx typically
employed a pH-sensitive matrix with entrapped or immobilized
GOx to cause a local decline of pH with increasing glucose
levels, which promoted insulin release through either
degradation or protonation.10,11,15,19 Recently, our group
reported a hypoxia-sensitive mechanism for achieving fast,
glucose-responsive, insulin delivery.20 We also demonstrated
that utilizing the rapid oxygen consumption during the
oxidation of glucose catalyzed by GOx as a trigger was able
to achieve fast insulin release under physiological conditions.
Herein, we report a new hypoxia and H2O2 dual-sensitive
diblock copolymer consisting of poly(ethylene glycol) (PEG)
and polyserine modified with 2-nitroimidazole via a thioether
moiety (designated PEG-poly(Ser-S-NI); Figure S1). The
thioether serves as a H2O2-sensitive moiety that turns the
polymer more hydrophilic when it is converted into a sulfone
by H2O2.
21−23 This amphiphilic polymer is able to self-
assemble into a nanoscaled bilayer vesicle structure (polymer-
some), which encapsulates recombinant human insulin and
GOx in the aqueous core. When exposed to a high blood
glucose level, the glucose diffuses across the polymeric bilayer
membrane and interacts with GOx (Figure 1a). During this
glucose oxidation process catalyzed by GOx, the dissolved
oxygen is rapidly consumed. The resulting local hypoxic
environment can promote the bioreduction of NI groups into
hydrophilic 2-aminoimidazoles catalyzed by a series of
nitroreducatases.20,24,25 During the enzymatic oxidation of
glucose, the undesirable byproduct H2O2 is also generated,
which may lead to free radical-induced damage to skin tissue
during the long-term usage26,27 and reduce the activity of GOx,
decreasing response rate.28,29 Generally, catalase (CAT) is
incorporated with GOx-based glucose-responsive systems to
scavenge H2O2.
30 However, oxygen regenerates during the
decomposition of H2O2 catalyzed by CAT, which reduces the
hypoxic level and leads to low release rate. The H2O2-sensitive
thioether moiety in PEG-poly(Ser-S-NI) has the capability of
effectively eliminating the undesirable H2O2 to assist GOx’s
catalysis. Meanwhile, the resulting sulfone groups convert the
polymer to a more water-soluble form. This change in chemical
structure promotes the dissociation of the dual-sensitive,
glucose-responsive polymersomes (d-GRPs) and subsequent
release of the encapsulated insulin.
In order to achieve convenient administration, the d-GRPs
can be further integrated with a painless microneedle (MN)
patch platform for insulin delivery.20,31−33 Once exposed to the
high interstitial fluid glucose after transcutaneous adminis-
tration, the d-GRPs loaded in MNs quickly disassociate to
release the entrapped insulin into the vascular and lymph
capillary network20,34 (Figure 1b). Furthermore, unlike non-
H2O2-sensitive GRP-loaded MNs, which may lead to a local
inflammation due to the rapid accumulation of H2O2, this
“smart insulin patch” (SIP) with a novel hypoxia and H2O2
dual-sensitive mechanism presents a promising approach for
tight glucose regulation and potential prevention of long-term
disease morbidity.
The diblock copolymer (PEG-polyserine) was first synthe-
sized via amine-initiated ring-opening.19 The (2-nitroimidazol-
1-yl)methanethiol, which rendered the polymer sensitive to
hypoxia and H2O2 (Figure S1), was conjugated to the hydroxyl
group of the serine residue through an allyl ether (PEG-
poly(Ser-S-NI)). For comparison purposes, we also synthesized
PEG-poly(Ser-NI) without the sulfonate by incorporating the
hydroxyl groups of PEG-polyserine with 1-(5-chloropentyl)-2-
nitroimidazole (Figure S1), which is only able to respond to
Figure 1. Schematic of the glucose-responsive insulin delivery system using hypoxia and H2O2 dual-sensitive polymersome-based vesicles (d-GRPs)
loading microneedle-array patches. (a) Formation and mechanism of d-GRPs comprised of PEG-poly(Ser-S-NI). (b) Schematic of local
inflammation induced by non-H2O2-senstive GRP-loaded microneedle-array patch, and schematic of d-GRP-loaded microneedle-array patch for in
vivo insulin delivery triggered by a hyperglycemic state for potential prevention of the long-term side effect associated with inflammation.
hypoxia. PEG-poly(Ser-NI) and serves as a control to confirm
the importance of the H2O2 elimination ability of PEG-
poly(Ser-S-NI).
The d-GRPs with encapsulated cargoes were formed by self-
assembly of PEG-poly(Ser-S-NI) through a solvent evaporation
method.1,19 As shown in Figure 2a, the transmission electron
microscopy (TEM) image showed that the d-GRPs had a
spherical structure, and a bilayer membrane with a thickness of
around 20 nm was clearly observed. The average diameter was
measured as 94 nm by dynamic light scattering (DLS) (Figure
2b). The successful encapsulation of insulin was further
confirmed by fluorescence microscopy imaging of the d-GRPs
with FITC-labeled insulin (Figure 2d). The insulin loading
capacity of d-GRPs was determined as 3.2%. Meanwhile, non-
H2O2 sensitive GRPs entrapping insulin and GOx were also
prepared from PEG-poly(Ser-NI) with the similar morphology
and size as a control (Figure S2).
The sensitivity of d-GRPs and GRPs to H2O2 was first
assessed by measuring the concentration of H2O2 using a
fluorimetric assay kit for hydrogen peroxide. The initial H2O2
solution (5 μM) showed high emission intensity after reaction
with a peroxidase substrate (Figure 2f). However, addition of d-
GRPs into the H2O2 solution produced a significant decline in
fluorescence intensity. Furthermore, the reduction in intensity
was dependent on the d-GRP concentration, while no
significant change in the concentration of H2O2 occurred
after incubation with GRP controls. Even more importantly, the
H2O2 elimination capability was assessed through incubation of
GOx-loaded vesicles with glucose. As shown in Figure 2g, H2O2
generated rapidly due to the oxidation of glucose when
incubating GRPs in PBS buffer [137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 2 mM KH2PO4 (pH 7.4)] consisting of 400
mg/dL glucose, while the produced H2O2 was almost
eliminated by d-GRPs.
In order to evaluate the glucose-responsive capability of d-
GRPs, vesicles were incubated with PBS buffer containing
various concentrations of glucose, including a typical hyper-
glycemic level (400 mg/dL), a normoglycemia level (100 mg/
dL), and a control level (0 mg/dL). In the presence of high
glucose level, the dissolved oxygen was rapidly consumed due
to the oxidation of glucose catalyzed by GOx. Using an oxygen-
sensitive phosphorescent molecular probe,35 a relatively lower
oxygen level was generated in the d-GRPs under the
hyperglycemia level compared to the other two control samples
Figure 2. Characterization of dual-sensitive polymersome-based vesicles (d-GRPs). (a) TEM images of d-GRPs encapsulating insulin and enzyme
pre- or postincubation with 400 mg/dL glucose for 20 min, 1 h, and 24 h. Scale bar is 100 nm. (b,c) Size distribution of d-GRPs pre- (b) and post-
(c) incubation with 400 mg/dL glucose for 24 h. (d,e) 2.5D fluorescence images of FITC-insulin loaded d-GRPs solution (d) pre- and post- (e)
incubated in 400 mg/dL glucose solution for 24 h at 37 °C. (f) The sensitivity of d-GRPs and GRPs to H2O2 assessed by a fluormetric hydrogen
peroxide assay kit. Student’s t test: *p < 0.05, ***p < 0.001. (g) The H2O2 generation rate of GOx-loaded d-GRPs or GOx-loaded GRPs incubated in
400 mg/dL glucose solution. (h) Phosphorescence lifetime profile for the GOx-loaded d-GRPs or GOx-loaded GRPs incubated with different
glucose concentration solutions containing an oxygen concentration molecule probe. (i) Decrease of UV absorption at 330 nm of d-GRPs in
different glucose concentrations at 37 °C. Error bars indicate SD (n = 3).
(Figure 2h). The oxygen concentration rapidly decreased
within the vesicles and reached equilibrium within 20 min.
Moreover, a significant slower oxygen consumption rate and
higher oxygen level was observed when incubating GRPs with
the same concentration in glucose solution. The lower oxygen
level in d-GRPs sample can be attributed to the effective H2O2
elimination ability of PEG-poly(Ser-S-NI), which avoids the
deactivation of GOx. Under such hypoxic condition, the NI
groups were effectively reduced by NADPH catalyzed by the
reductase.20,24,36 Correspondingly, the characteristic absorbance
of NI at 330 nm gradually declined over time,37 confirming the
conversion of hydrophobic NI groups to hydrophilic 2-
aminoimidazoles groups (Figure 2i). Because of the generation
of hydrophilic 2-aminoimidazoles and sulfone on PEG-
poly(Ser-S-NI), the d-GRPs began to dissociate and sub-
sequently released the encapsulated cargoes. The correspond-
ing change in morphology and size were clearly observed by
transmission electron microscopy and dynamic light scattering
(Figure 2a,c). Furthermore, the release of FITC-labeled insulin
was validated using fluorescence microscopy. As shown in the
2.5D fluorescence images, the d-GRPs contain less insulin and a
present homogeneous distribution after incubation with 400
mg/dL glucose solution, confirming the glucose-triggered
insulin release (Figure 2e).
The quick release of insulin was obtained after exposure to a
high glucose solution due to the dissociation of d-GRPs, while
only a small amount of released insulin was observed in the
control samples under 0 or 100 mg/dL glucose levels (Figure
3a,b). Furthermore, a pulsatile release profile of insulin was
achieved when d-GRPs were alternatively immersed in the
normal and hyperglycemic solutions for several cycles (Figure
3c). The release rates changed in response to the change of
glucose levels, indicating the disassociation of d-GRPs, and the
amount of insulin released was dependent on the glucose
concentration. The insulin release rate could also be varied by
altering the GOx concentration. A maximum of an 11.2-fold
difference in insulin release rate was observed after incubation
under 100 or 400 mg/dL glucose levels for 2 h when reducing
the weight ratio of GOx to insulin to 1:40 (Figure S3).
Additionally, the insulin itself was not denatured during the
encapsulation or release procedures; the secondary conforma-
tional structure, measured using circular dichroism, of released
insulin from d-GRPs did not change compared to that of the
native insulin (Figure S4).
In order to achieve convenient and painless administra-
tion,20,38 d-GRPs were integrated with a cross-linked MN-array
patch composed of cross-linked hyaluronic acid using a
micromolding approach. The resulting MNs were arranged in
a 20 × 20 array, and each needle was of conical shape with
diameters of 300 μm at the base and 10 μm at the tip and a
height of 600 μm (Figure 4a,b). The fluorescence image in
Figure 4c displays a representative rhodamine-labeled MN with
FITC-insulin-loaded d-GRPs, indicating d-GRPs were well
distributed in the tip region of each needle. The mechanical
strength of the MN was measured as 3 N/needle using a tensile
compression machine (Figure S5), which was sufficient for skin
insertion without breaking.31
We next evaluated the in vivo efficacy of the SIP for diabetes
treatment using streptozotocin-induced adult type 1 diabetic
C57BL/6J mice. The diabetic mice were randomly divided into
four groups (n = 5) and the following patches transcutaneously
attached: the empty MNs containing only cross-linked HA,
MNs loaded with human recombinant insulin, MNs loaded
with d-GRPs encapsulating GOx and insulin [d-GRP(E+I)],
and MNs loaded with d-GRPs encapsulating insulin only [d-
GRP(I)] (insulin dose: 10 mg/kg). The trypan blue staining of
needle penetration sites was clearly observed on the excised
skin sample, and the hematoxylin and eosin (H&E)-stained
slide further verified that MNs could easily penetrate to the
epidermis (Figure S6), which exposed the d-GRPs to the
interstitial fluid. After removal of the MNs, the punctures in the
skin rapidly disappeared and were not evident at 4 h (Figure
S7).
The BGLs of each group were closely monitored after
administration. As shown in Figure 4d, a rapid decline of BGLs
was observed in the group treated with d-GRP(E+I)-loaded
MNs in the first 1 h, and the BGLs maintained in a normal state
for up to 6 h without peaks of hypoglycemia. In contrast,
without the enzyme GOx, the BGLs of mice treated with d-
GRP(I)-loaded MNs did not show an obvious decrease,
indicating that d-GRPs were highly stable in normal tissues.
Correspondingly, the plasma human insulin levels in mice
treated with d-GRP(E+I)-loaded MNs were higher than those
treated with d-GRP(I)-loaded MNs for at least 24 h (Figure
4e).
To further investigate the in vivo glucose control capability of
MNs, an additional administration with MNs was performed
2.5 h post the first administration. Unlike the group
administered with free insulin-loaded MNs, the BGLs of the
Figure 3. In vitro glucose-responsive release of insulin from d-GRPs. (a) In vitro accumulated insulin released from the d-GRPs in several glucose
concentrations at 37 °C. (b) Self-regulated profiles of the d-GRPs present the rate of insulin release as a function of glucose concentration. (c)
Pulsatile release profile of d-GRPs presents the rate of insulin release as a function of glucose concentrations (100 and 400 mg/dL). Error bars
indicate SD (n = 3).
mice administered with d-GRP(E+I)-loaded MNs did not
further decline to a hyperglycemic state (Figure 4f), supporting
the idea that these smart insulin patches can efficiently avoid a
risk of hypoglycemia. More importantly, the application of an
additional patch was able to significantly prolong the treatment
efficacy in response to the elevated BGLs compared to one
patch.
Next, an intraperitoneal glucose tolerance test (IPGTT)17
was performed at 1.5 h after administration of MNs in order to
further evaluate the dynamic of insulin release in vivo. The
BGLs of diabetic mice treated with d-GRP(E+I)-loaded MNs
showed a relatively delayed increase after glucose injection and
then rapidly declined to a normoglycemic state within 60 min
(Figure 4g). In sharp contrast, the mice treated with insulin-
loaded MNs showed a gradual increase in blood glucose in 120
min. To quantitate the glucose response to the various MNs,
the area under the curve was calculated between 0 and 120 min
for each group. As shown, the d-GRP(E+I)-loaded adminis-
tered mice showed significantly enhanced glucose responsive-
ness to the glucose challenge (Figure 4h).
To examine the potential for induction of hypoglycemia by
MNs further, we studied their effect on the healthy mice. As
shown in Figure 4i, the insulin-loaded MNs produced
remarkably reduced BGLs compared to d-GRP(E+I)-loaded
MNs-treated mice, indicating that there was little insulin leak in
d-GRP-loaded MNs. The corresponding hypoglycemia index
was calculated to measure the risk of hypoglycemia. d-GRPs-
loaded MNs exhibited a remarkable reduced hypoglycemia
index compared to the free insulin-loaded MNs (Figure 4j).
To study the biocompatibility of MNs loaded with d-GRPs,
both d-GRPs-loaded MNs and GRPs-loaded MNs without
H2O2 eliminating ability were transcutaneously attached to a
Figure 4. In vivo studies of the MN-array patches for type 1 diabetes treatment. (a) Photos of MNs array. Scale bars are 1 mm. (b) A scanning
electron microscopy image of MNs array. Scale bar is 200 μm. (c) A fluorescence microscopy image of rhodamine-labeled MNs loading d-GRPs with
FITC-labeled insulin. Scale bar is 500 μm. (d,e) In vivo studies of the MN-array patches for type 1 diabetes treatment: blood glucose levels (d) and
plasma human insulin concentrations (e) in streptozotocin-induced diabetic mice after treatment with blank MNs containing only cross-linked HA,
MNs loaded with human recombinant insulin, MNs loaded with d-GRPs containing insulin and enzyme (d-GRP(E+I)), or MNs loaded with d-GRPs
containing insulin (d-GRP(I)). *p < 0.05 for administration with d-GRP(E+I)-loaded MNs compared with administration of d-GRP(I). (f) The
blood glucose changes of mice treated with additional administration with MN-array patch 1 h post administration of d-GRP(E+I)-loaded MNs. (g)
In vivo glucose tolerance test toward diabetic mice 1.5 h post administration of d-GRP(E+I)-loaded MNs or insulin-loaded MNs in comparison with
the healthy control mice. (h) The responsiveness was calculated based on the area under the curve in 120 min with the baseline set at the 0 min
blood glucose reading. *p < 0.05 for administration with d-GRP(E+I)-loaded MNs compared with administration of insulin-loaded MNs. (i) The
blood glucose changes of healthy mice administrated with MN-array patch over time. *p < 0.05 for administration with d-GRP(E+I)-loaded MNs
compared with insulin-loaded MNs. (j) Quantification of hypoglycemia index, which was calculated from the difference between the initial and nadir
blood glucose readings divided by the time at which nadir was reached. *p < 0.05 for administration with d-GRP(E+I)-loaded MNs compared with
insulin-loaded MNs. The black arrows indicate the administration points. Error bars indicate SD (n = 5).
single mouse at different sites. Meanwhile, the pure hyaluronic
acid MNs were attached to the same mouse as a negative
control. Under a high GOx dose (3 mg/kg), obvious skin
damage was observed at the site where GRP(E)-loaded MNs
had been attached for 2 days, while there were no significant
lesions at the sites treated with d-GRP(E)-loaded MNs or pure
hyaluronic acid MNs (Figure 5a). The histological images using
H&E staining showed that GRP(E)-loaded MNs caused
neutrophil infiltration (Figure 5c top), indicating a pathophy-
siological response and tissue damage induced by the generated
H2O2. In contrast, no significant pathological abnormalities
occurred in the site treated with d-GRP(E)-loaded MNs.
Moreover, the skin tissue stained with the in situ terminal
deoxyribonucleotidyl transferase (TDT)-mediated dUTP-di-
goxigenin nick end labeling (TUNEL) assay clearly showed the
cell apoptosis in the skin sample treated with GRP(E)-loaded
MNs, whereas no cell death in the skin tissue treated with the
d-GRP(E)-loaded MNs and pure hyaluronic acid MNs (Figure
5c bottom). Furthermore, insignificant pathological abnormal-
ity was observed in skin tissue after a 2 week treatment of d-
GRP(E+I)-loaded MNs with a normal GOx dose of 1 mg/kg
(Figure S8). A long-term safety assessment will be further
performed on diabetic minipigs, the skin of which has more
similar physical and physiological properties to that of human
beings.39 The cytotoxicity of bare d-GRPs toward HeLa cells
was evaluated by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-dipheny-
tetrazoliumromide (MTT) assay. As presented in Figure 5b, the
bare d-GRPs did not show significant toxicity within all the
studied concentrations.
In conclusion, an effective glucose-responsive insulin delivery
strategy has been exploited utilizing vesicles sensitive to both
hypoxia and H2O2. A local hypoxic environment can be quickly
generated due to the oxygen consumption during the enzymatic
conversion of glucose to gluconic acid, which facilitates the
solubility switch of the polymer through the bioreduction of NI
groups on the side chains. Moreover, the thioether moiety
within the designed polymer not only responds to H2O2, the
byproduct during glucose oxidation, to promote the dis-
assembly of vesicles, but also eliminates the excess H2O2 to
maintain the activity of GOx and circumvent the damage to
skin tissue. Furthermore, the d-GRPs can be integrated within a
cross-linked HA-based MN-array patch to achieve convenient,
painless, and continuous administration of insulin. The in vivo
studies demonstrated that this SIP was highly effective in tight
regulation of BGLs in diabetic mice and showed minimal side
effects regarding inflammation. Additionally, this dual-sensitive
formulation strategy displays the potential benefit in controlled
delivery for other therapeutic agents under hypoxia and high
oxidative stress.40 For potential translation of this microneedle
array patch-based formulation, efforts associated with further
Figure 5. Biocompatibility evaluation of d-GRP-loaded MNs. (a) Photograph of a mouse transcutaneously administrated with pure hyaluronic acid
(HA) MNs, GRP-loaded MNs, and d-GRP-loaded MNs at different sites. (b) Cytotoxicity study of bare d-GRPs after 24 h incubation with HeLa
cells. Error bars indicate SD (n = 6). (c) Micrographs of mouse skin tissue at the treated sites. Skin tissue was collected from the mouse shown in
panel a. Top: H&E stained images. Bottom: Histology stain with TUNEL assay (green) and Hoechst (blue). Scale bar: 100 μm.
enhancement of loading capability and bioavailability are
expected. In addition, by tuning physicochemical property of
major material as well as formulation composites, optimization
of glucose-responsive pharmacokinetics in order to mimic that
of healthy pancreatic cells is also essential. Thorough
characterization utilizing animals equipped with the continuous
glucose monitoring systems (CGMSs) would facilitate to
obtain detailed information to guide the improvement.
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